Changeflow GovPing Healthcare & Life Sciences Novozymes A/S Alpha-Amylase Enzyme Variants and...
Priority review Rule Added Final

Novozymes A/S Alpha-Amylase Enzyme Variants and Polynucleotides Patent Application

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

Novozymes A/S has filed US Patent Application US20260109960A1 (Application No. 19363135) titled 'ENZYME VARIANTS AND POLYNUCLEOTIDES ENCODING THE SAME', published April 23, 2026, with a filing date of October 20, 2025. The application covers polypeptides with alpha-amylase activity, encoding polynucleotides, nucleic acid constructs, vectors, host cells, and associated production methods. CPC classifications include C12N 9/2414, C11D 3/386, and related biotechnological categories indicating commercial applications in cleaning products and industrial enzyme production. Eight named inventors are listed, including Torsten Bak Regueira, Bitten Plesner, Thomas Holberg Blicher, Anne Dorte Houg, Sofia Arnehed, Lars Lehmann Hylling Christensen, and Carsteen Andersen.

“The present invention relates to polypeptide having alpha-amylase activity.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 236 changes logged to date.

What changed

Novozymes A/S filed US Patent Application US20260109960A1 on October 20, 2025, published April 23, 2026, seeking exclusive rights to enzyme variants with alpha-amylase activity, the polynucleotides encoding those variants, and associated nucleic acid constructs, vectors, host cells, and methods of use. The application is classified under multiple CPC codes including C12N 9/2414 (amylases), C11D 3/386 (enzyme preparations for cleaning), and C12N 15/52 (recombinant DNA technology, indicating biotechnological production methods.

Parties in the industrial enzyme sector, particularly firms developing or commercializing alpha-amylase products for cleaning, textile, or food-processing applications, should monitor this application through the USPTO's public dossier. Competitors may wish to conduct freedom-to-operate analyses as the claims mature toward grant, particularly in jurisdictions where Novozymes holds corresponding foreign filings.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

ENZYME VARIANTS AND POLYNUCLEOTIDES ENCODING THE SAME

Application US20260109960A1 Kind: A1 Apr 23, 2026

Assignee

Novozymes A/S

Inventors

Torsten Bak Regueira, Bitten Plesner, Thomas Holberg Blicher, Anne Dorte Houg, Sofia Arnehed, Lars Lehmann Hylling Christensen, Carsten Andersen

Abstract

The present invention relates to polypeptide having alpha-amylase activity. The present invention also relates to polynucleotides encoding the polypeptides; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the polypeptides.

CPC Classifications

C12N 9/2414 C11D 3/386 C12N 1/14 C12N 1/20 C12N 9/2417 C12N 15/52 C12N 15/63 C12Y 302/01001

Filing Date

2025-10-20

Application No.

19363135

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing Enzyme research and development Biotech IP protection
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!